Business, energy, technology, markets and global industry news from Business News Today

Korlym

PharmaDeviceNews Korlym
Corcept Therapeutics’ second-quarter results will put early Lifyorli launch momentum, Korlym growth and the relacorilant FDA review under close scrutiny. Representative image.
Pharma & Biotech

Corcept Therapeutics sets July 29 Q2 call as Lifyorli launch and relacorilant review take centre stage

Corcept Therapeutics will report Q2 results on July 29, with Lifyorli launch sales, Korlym growth and relacorilant’s FDA review in focus.

Read More
Representative image: Corcept Therapeutics has resubmitted the relacorilant New Drug Application for Cushing’s syndrome, reopening FDA scrutiny of efficacy, trial design and liver safety evidence.
Pharma & Biotech

Corcept revives its Cushing’s bid with relacorilant, yet the hardest evidence gap remains

Read how Corcept’s relacorilant NDA resubmission could reshape Cushing’s treatment while efficacy and liver safety questions remain.

Read More
Representative image of clinical diabetes data review, highlighting Corcept’s Korlym findings in hypercortisolism-linked type 2 diabetes and GLP-1 treatment outcomes.
Pharma & Biotech

Corcept’s Korlym data put hypercortisolism back in focus for cardiometabolic disease

Read how Corcept’s ADA data could reshape hypercortisolism screening in difficult-to-control type 2 diabetes and GLP-1 care.

Read More
Medical Devices & Diagnostics

Corcept Therapeutics expands hypercortisolism evidence base with largest US resistant hypertension screening trial

Corcept's MOMENTUM trial finds hypercortisolism in 27.3% of resistant hypertension patients. Explore what this means for screening and treatment. Read more.

Read More